BVIKM - 30ième symposium

30ième symposium

WHAT WILL CHANGE IN YOUR DAILY PRACTICE WITH THE NEW EUCAST BREAKPOINTS FOR ANTIBIOTIC SUSCEPTIBILITY TESTING?

European breakpoints and EUCAST, what next? [Gunnar KAHLMETER (Central Hospital, Växjö, Finlande)]
PK-PD as a basis for clinically relevant breakpoints. [Paul TULKENS (UCL, Bruxelles)]
Introduction of new breakpoints in the labs: challenges and solutions. [Pierrette MELIN (CHU de Liège, Liège)]
Epidemiological consequences of new breakpoints. [Greet IEVEN (UZ Antwerpen, Anvers)]
Consequences for the clinicians. [Yves VAN LAETHEM (CHU Saint-Pierre, Bruxelles)]